explore -WSS

explore

author：knowledge 2025-10-01 00:59:40 - browse：13

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： How a scoliosis diagnosis changed the life of one young dancer

hotspot

WSS

White House finalizes ITC's import ban of latest Apple Watches

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Why psychiatrists like me stop taking insurance

Chronically ill young patients struggle to find fertility info

Altering the blood type of lungs raises potential for universal organs for transplants

Why psychiatrists like me stop taking insurance

explore

explore

focus

Malaria cases in Florida and Texas: Here’s what you need to know

UCB departs biotech trade group BIO

DIEP, the 'gold standard' of breast reconstruction, is under threat

Feng Zhang, Grail founder join forces on new gene editing startup

Peter Hotez and the public health issue of online harassment

Altering the blood type of lungs raises potential for universal organs for transplants

New air purifier tech could be key to improving indoor air quality

3 medical device trends to watch in 2024

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

entertainment

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

3 medical device trends to watch in 2024

FDA approves first new drug developed for postpartum depression

Biden administration plans revamp of organ transplant system

UCB departs biotech trade group BIO

Goldman Sachs launches $650M fund for life science investments

hotspot

hotspot

hotspot

focus